Nvidia powers AI agents for Silo Pharma and Certara in drug development push

Nvidia Powers AI Agent Strategies for Certara, Silo Pharma - NVIDIA (NASDAQ:NVDA)

Certara is integrating Nvidia's BioNeMo Agent Toolkit into its AI-driven drug development platform, while Silo Pharma's subsidiary, QwikAgents, has joined the Nvidia Developer Program to strengthen its AI agent capabilities. * Nvidia stock is gaining positive traction. Why are NVDA shares climbing? Certara Integrates Nvidia BioNeMo Into AI Drug Development Platform Certara said it is partnering with Nvidia to advance its open, integrated AI platform by combining its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks. Under the collaboration, the Nvidia BioNeMo Agent Toolkit will become one of several agentic frameworks available within Certara's platform. The toolkit is designed to turn AI agents into autonomous life sciences researchers by providing access to Nvidia's life sciences technology stack while complementing Certara's biosimulation models, regulatory expertise and scientific teams. AI Agents Target Drug Development Workflows According to Certara, specialized AI agents will analyze scientific models, datasets and domain expertise across multiple stages of drug development. The company said these agents can support tasks such as optimizing dosing strategies using systems pharmacology models, analyzing clinical datasets, simulating patient and clinical trial scenarios, evaluating ADMET properties, assembling regulatory-ready evidence and assessing early-stage drug discovery hypotheses. Certara added that the technology is intended to enhance the work of biosimulation experts and scientific teams by accelerating insight generation while keeping scientists at the center of decision-making. Silo Pharma Subsidiary Joins NVIDIA Developer Program Separately, Silo Pharma announced its wholly owned subsidiary, QwikAgents, has joined the Nvidia Developer Program. The company said QwikAgents' platform automates complex workflows using autonomous AI agents capable of reasoning, taking action and interacting with enterprise systems. The platform also incorporates persistent memory, intelligent routing across multiple large language model providers, browser automation and secure data management to support scalable AI-driven operations. Silo Pharma said participation in the Nvidia Developer Program will provide QwikAgents with access to Nvidia's AI software ecosystem, development frameworks, technical training and optimization resources. The company expects those resources to help accelerate platform enhancements as it expands AI agent capabilities for enterprise customers. CERT/SILO Stock Price Activity: Certara shares were down 0.63% at $7.09, Silo Pharma shares were down 2.10% at $6.09 at the time of publication on Tuesday, according to Benzinga Pro data. Image via Shutterstock/ Alexander56891 Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Silo Pharma subsidiary joins NVIDIA developer program By Investing.com

SARASOTA, FLA. - Silo Pharma (Nasdaq:SILO) announced today that its wholly owned subsidiary, QwikAgents, has joined the NVIDIA Developer Program. The program provides access to NVIDIA's AI software ecosystem, development frameworks, technical training, and optimization resources for AI application development and deployment, according to a press release statement. QwikAgents operates an AI-agent platform designed to automate workflows through autonomous AI agents. The platform includes persistent memory, model routing across multiple large language model providers, browser automation, and data management features. Through the NVIDIA Developer Program, QwikAgents will receive access to development tools and resources. The company stated these resources could support enhancements to its platform as it seeks to expand capabilities for enterprise customers.Parent company Silo Pharma, trading at a market cap of $6.75 million, maintains a strong financial position with more cash than debt on its balance sheet and a current ratio of 9.65, according to InvestingPro data. The stock has gained nearly 22% year-to-date, though InvestingPro analysis suggests the company remains undervalued relative to its Fair Value. "The rapid adoption of AI agents is creating demand for platforms that can deploy, manage, and scale autonomous AI systems across the enterprise," said Eric Weisblum, CEO of Silo Pharma. Silo Pharma is a developmental-stage biopharmaceutical company focused on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio includes SPC-15 for post-traumatic stress disorder, SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer's disease. QwikAgents was established as a wholly-owned subsidiary of Silo Pharma and focuses on enterprise workflow automation through its AI-agent platform. The platform routes across eight large language model providers and includes encrypted backups and browser automation capabilities. In other recent news, Silo Pharma has reported stability data for its investigational intranasal treatment, SPC-15. The company confirmed that the drug maintained its physical, chemical, and microbiological integrity over nine months under real-time testing conditions. Additionally, Silo Pharma has regained compliance with Nasdaq's minimum closing bid price requirement, as confirmed by the Nasdaq Stock Market LLC. This compliance ensures that the company's stock continues to trade on the Nasdaq Capital Market without issue. Furthermore, Silo Pharma announced a 1-for-15 reverse stock split of its common stock, which will take effect shortly. In another development, the company filed a provisional patent for an ibogaine-based treatment aimed at traumatic brain injury and related neuropsychiatric conditions. Lastly, Silo Pharma has launched a new subsidiary to operate its recently acquired AI platform, Qwikagents.ai, while advancing its PTSD drug program. These recent developments highlight Silo Pharma's ongoing strategic initiatives in drug development and technological advancement. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.